5-HTP for Fibromyalgia

5-HTP has genuine but dated trial support in fibromyalgia. The serotonin syndrome risk alongside SSRIs, SNRIs and tramadol makes it a supervised option rather than a casual one.

5-HTP is the immediate precursor to serotonin and crosses the blood-brain barrier without the transport competition that limits tryptophan. Enhanced serotonergic tone supports descending pain inhibition and improves slow-wave sleep, both deficient in fibromyalgia.

Randomised placebo-controlled trials in the late 1980s and early 1990s using 100 mg three times daily reported significant reductions in tender point count, pain severity, morning stiffness and anxiety, with improvements in sleep. Sample sizes were small and the diagnostic criteria differ from those used today, so the results have not been rebuilt with modern methodology. The mechanism aligns with the established efficacy of serotonin-noradrenaline reuptake inhibitors such as duloxetine and milnacipran in fibromyalgia, which lends coherence to the older findings. That same overlap is the main safety concern: combining 5-HTP with prescribed serotonergic drugs risks serotonin syndrome, so it should only be trialled with clinician oversight and not stacked onto existing antidepressant therapy.

People already on an SNRI have limited headroom for further serotonergic effect, and those whose main problem is deconditioning will not improve from a sleep-oriented intervention alone.